Endothelial modulation of contractile responses in arteries from hypertensive rats. 1996

Y Dohi, and M Kojima, and K Sato
Second Department of Internal Medicine, Nagoya City University Hospital, Japan.

The endothelium plays an important role in the circulation by modulating contractile responses of vascular smooth muscle. We designed this study to investigate the alterations of endothelial modulation in hypertension. Rings of femoral arteries were prepared from Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR), and changes in isometric tension were recorded. In rings with endothelium, norepinephrine (in either the presence or absence of yohimbine) evoked concentration-dependent contractions. Endothelium removal markedly enhanced the contraction; both the maximal response and sensitivity were increased, and these responses were less pronounced in SHR than WKY. In contrast to norepinephrine-induced contractions, the enhancement of prostaglandin F2 alpha-or serotonin-induced contractions after endothelium removal was small and comparable in WKY and SHR; sensitivity was increased, but the maximal response was not. N omega-Nitro-L-arginine methyl ester enhanced the contractions induced by these agonists in arteries with but not without endothelium and thereby abolished the enhancement of the contractions after endothelium removal. Thus, the endothelium plays an inhibitory role against contractions in rat femoral arteries by releasing nitric oxide, but the characteristics of the endothelial inhibition are not identical against various types of contractions. The negative endothelial modulation is more pronounced during alpha 1-adrenoceptor-mediated contractions than during contractions mediated by other receptors. The inhibitory role of the endothelium against alpha 1-adrenoceptor agonist-induced but not serotonin- or prostaglandin F2 alpha-induced contraction is impaired in hypertension.

UI MeSH Term Description Entries
D008297 Male Males
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D011921 Rats, Inbred WKY A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR). Rats, Wistar Kyoto,Wistar Kyoto Rat,Rats, WKY,Inbred WKY Rat,Inbred WKY Rats,Kyoto Rat, Wistar,Rat, Inbred WKY,Rat, WKY,Rat, Wistar Kyoto,WKY Rat,WKY Rat, Inbred,WKY Rats,WKY Rats, Inbred,Wistar Kyoto Rats
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

Y Dohi, and M Kojima, and K Sato
November 1994, Clinical and experimental hypertension (New York, N.Y. : 1993),
Y Dohi, and M Kojima, and K Sato
December 1995, Hypertension (Dallas, Tex. : 1979),
Y Dohi, and M Kojima, and K Sato
August 1993, The American journal of physiology,
Y Dohi, and M Kojima, and K Sato
October 1990, British journal of pharmacology,
Y Dohi, and M Kojima, and K Sato
April 2011, Clinical and experimental pharmacology & physiology,
Y Dohi, and M Kojima, and K Sato
August 1988, European journal of pharmacology,
Y Dohi, and M Kojima, and K Sato
February 1975, Laboratory investigation; a journal of technical methods and pathology,
Copied contents to your clipboard!